To improve the efficacy of tumor cell-based and dendritic cell (DC)-based cancer vaccines, this study explored the potential of a new cancer vaccine strategy, that is, the use of CD40 ligand-transfected tumor (CD40L-tumor) cells to simultaneously deliver both tumor-derived antigens (Ag) and maturation stimuli to DCs. Materials from frozen/thawed or irradiated human tumor cells, with or without surface CD40L, were internalized efficiently by immature DCs after coincubation. However, during the internalization process, only coculturing with irradiated CD40L-tumor cells resulted in concurrent, optimal DC maturation and production of proinflammatory chemokines and pro-Th1 cytokines, such as IL-6, IL-8, IL-12, IFN-g, and TNF-a. These activated DCs were the most potent cells to support the growth of CD8 þ , IFN-g-producing T cells, and to process tumor Ag for the generation of specific cytotoxic T cells in vitro. Animals vaccinated with irradiated CD40L-tumor cell-pulsed DCs were better protected against subsequent challenge of a weakly immunogenic tumor cell line than animals vaccinated with irradiated CD40L-tumor cells alone. Thus, our results strongly support the future clinical application of using DCs pulsed with irradiated CD40L-tumor cells as a cancer vaccine.
D
endritic cells (DCs) are ''professional'' antigen presenting cells (APCs) involved in the initiation and maintenance of both the innate and the adaptive immune responses. 1 Protective cellular immunity was induced by vaccination of DCs loaded with various forms of tumor antigens (Ag) in several animal models. [2] [3] [4] Early clinical trials using tumor Ag-pulsed DCs as vaccines for the treatment of various advanced malignancies have been reported. [5] [6] [7] Several DC-based clinical trials employed preidentified tumor-associated Ag (TAA) or synthetic peptides containing cytotoxic T lymphocyte (CTL) epitopes of known TAA as the source of Ag. Alternative approaches have been explored to expand DC-based therapy to cancers for which appropriate TAA or relevant CTL epitopes have not been determined. These approaches include pulsing DCs with tumor cell lysates, 3, 4, 6, 8, 9 tumor-derived RNA, 10 necrotic or apoptotic tumor cells, [11] [12] [13] [14] [15] and fusing DCs with tumor cells. 16, 17 Gene-modified tumor cell vaccines, which also use undefined tumor material as the source of tumor Ag, represent another promising new approach for cancer therapy. Immunization of animals with tumor cells transfected with genes coding for costimulatory molecules, cytokines, or chemokines can induce tumor-specific CTL responses and inhibit the growth of parental tumor cells. [18] [19] [20] [21] One possible mechanism underlying the antitumor effect of gene-modified tumor cell vaccine is that tumor materials deposited at the injection site are captured and subsequently presented to specific CTLs by infiltrating or resident DCs. 22 Thus, tumor cells transfected with genes that can promote such in vivo Ag presentation processes are likely to serve as good tumor vaccines. It has been shown that immunization with CD40 ligand (CD40L)-transfected tumor (CD40L-tumor) cells can induce a protective immunity against tumor challenge in animal models. [22] [23] [24] CD40L induces DC maturation and triggers DCs to secrete various cytokines, including IL-12, which are important in the induction of Th1 and CTL responses. [25] [26] [27] Signaling through CD40 on the surface of DCs plays an important role in DC migration from the epidermal tissue to the lymph nodes, 28 and can enable DCs to activate CTL in the absence of Th cells.
Vaccination with CD40L-tumor cells could potentially result in the uptake of tumor Ag by infiltrating DCs, and the concurrent activation of DCs. Thus, the antitumor immune response to CD40L-tumor cells could be more potent than the one to unmodified tumor cells. However, with this approach, it is difficult to optimally control and monitor the efficiency of Ag loading and activation of DCs in vivo. To overcome this drawback and utilize the benefit of CD40L signaling, we incorporated the genemodified tumor cells with the DCs prior to vaccination.
In this study, we have used an in vitro system to investigate the effect of coculturing human immature DCs with different forms of human CD40L-tumor cells. By using CD40L-tumor cells to deliver both tumor Ag and stimulating signals to DCs during in vitro vaccine preparation, we had better control of Ag loading and activation of DCs. DCs cultured with irradiated CD40L-tumor cells were able to process and present tumor Ag, secrete substantial amounts of various pro-Th1 and proinflammatory cytokines, and promote the growth and generation of specific CD8 þ T cells. When CD40L-tumor cell-vaccinated animals were compared to animals receiving DCs pulsed with irradiated CD40L-tumor cells, the latter were found to be more resistant to subsequent challenge with a weakly immunogenic B16-F1 tumor line. Our results support DCs pulsed with irradiated CD40L-transfected tumor cells as a candidate vaccine strategy in human clinical studies and may provide the foundation for the design of a better DC-based cancer vaccine.
Materials and methods

Human tumor transfectant expressing CD40L
A lung cancer cell line was previously established in our laboratory from the pleural effusion of a lung cancer patient. The lung cancer cells were transfected with either an empty pcDNA3.1/Zeo(À) vector or a vector carrying the human CD40L sequence and selected with 200 mg/ml zeocin (Invitrogen, San Diego, CA). The expression of CD40L by transfected tumor cells was determined by staining with a PE-anti-CD154 mAb (BD PharMingen, San Diego, CA). Cells expressing surface CD40L were sorted using a FACS Vantage cell sorter (Becton Dickinson, Mountain View, CA) and cloned. All cell lines used in this study were negative for mycoplasma contamination as determined by a nested PCR-based mycoplasma detection kit (ATCC, Rockville, MD).
Preparation of human DCs
Peripheral blood mononuclear cells (PBMCs) from healthy donors (obtained from the Chinese Blood Foundation) were enriched by density-gradient centrifugation with Ficoll-Hypaque (Amersham Pharmacia Biotech, Uppsala, Sweden). Cells at the interface were collected, washed and suspended in serum-free AIM-V medium (Life Technologies, Rockville, MD). Cells were plated into plastic tissue culture dishes (25 Â 10 6 cells/ dish) and incubated at 371C for 2 hours. Adherent mononuclear cells were cultured with RPMI-1640 medium with 10% fetal bovine serum (FBS) in the presence of 1000 U/ml recombinant human IL-4 (Peprotech, Rock Hill, NJ) and 500 U/ml granulocyte-macrophage colonystimulating factor (GM-CSF) (a gift from Kirin Brewery Co., Japan). After 7 days, nonadherent and loosely adherent cells were collected and used as the source of immature DCs in the subsequent experiments.
Flow cytometric analysis
Cells to be analyzed for the expression of surface markers were stained with different fluorescence-labeled mAb and then analyzed using a flow cytometer (EPICS XL-MCL, Beckman Coulter, Fullerton, CA). The mAbs used in this study were as follows: flourescein isothiocyanate (FITC)-anti-HLA-DR (Immunotech, Marseille Cedex, France), phycoerythrin (PE)-anti-CD86 (Immunotech), FITCanti-CD80 (Immunotech), PE-anti-CD83 (BD PharMingen), and PE-anti-CD11c (Immunotech). Isotypematched control mAb were obtained from BD PharMingen and Caltag (Burlingame, CA).
Internalization of tumor materials by DCs
Tumor cells were labeled with a green fluorescent dye, PKH67 (Sigma, St. Louis, MO) according to the manufacturer's instruction, and treated with one cycle of freezing/thawing to induce necrosis or irradiation (12,000 rad) to initiate apoptosis. One cycle of freezing/ thawing resulted in mostly intact cells that were stained positive with trypan blue. Irradiation (12,000 rad) initiated a slowly progressing apoptosis, as 10-20% cells were stained positive with FITC-annexin V (Caltag) after 16 hours. DCs (1 Â 10 6 cells) were cultured with equal numbers of frozen/thawed or irradiated dye-labeled tumor cells at 371C for 16 or 40 hours. The mixture of cells was collected, and DCs were counterstained with a PE-anti-CD11c mAb (Immunotech) or a PE-anti-CD83 mAb (BD PharMingen). The internalization of green fluorescent tumor materials by DCs was evaluated with a fluorescent microscope (BX50, Olympus, Tokyo, Japan) or a flow cytometer (EPICS XL-MCL, Beckman Coulter).
Induction of maturation and activation of DCs
Immature DCs (2.5 Â 10 5 cells/well) were cultured in a 24-well plate with equal numbers of frozen/thawed or irradiated tumor cells with or without CD40L expression. Cells were collected after 16 or 40 hours and analyzed for surface expressions of CD11c, CD83, CD80, CD86, and HLA-DR by flow cytometry, or for the induction of an allogeneic mixed leukocyte response (MLR). In some experiments, the culture supernatants were harvested and assayed for cytokine production.
Detection of cytokine production
The production of IL-12p70, IL-1b, IL-6, IL-8, IL-10, and TNF-a in the culture supernatant was detected by a Human Inflammation Cytometric Bead Array (CBA) Kit (BD PharMingen). Briefly, beads of different FL-3 fluorescent intensities were preconjugated with mAb against various cytokines by the manufacturer. These beads were incubated with 50 ml of culture supernatants (or cytokine standards) and PE-labeled mAb against various cytokines at room temperature for 3 hours. Beads were then subjected to flow cytometric analysis. The amount of a given cytokine in the culture supernatant was calculated by converting the intensity of PE fluorescence to concentration after comparing to results obtained with the cytokine standards. The production of IFN-g in the culture supernatant was detected by a sandwich-ELISA using an IFN-g-OptEIA set (BD PharMingen). T-cell surface marker, secreted and intracellular cytokine analysis DCs were cultured with different forms of tumor cells for 40 hours. After washing, tumor material-pulsed DCs (2.5 Â 10 5 cells/well) were cultured with allogeneic, nonadherent PBMCs (2.5 Â 10 6 cells/well) for 6 days. Proliferating T cells were expanded with 20 U/ml IL-2 (Chiron, Amsterdam, The Netherlands) and cultured for another 6 days. Cells were then collected and stained with an FITC-anti-CD8 mAb and a PE-anti-CD3 mAb (Immunotech). The forward scatter (FSC) and the side scatter (SSC) were used to gate on small lymphocytes for subsequent analysis. For intracellular cytokine staining, proliferating T cells were collected, washed and stimulated with 20 ng/ml phorbol 12-myristate-13-acetate (PMA) and 1000 ng/ml ionomycin (Sigma) in the presence of GolgiStop (BD PharMingen) for 6 hours. Cells were stained with an FITC-anti-CD8 mAb. After washing, cells were fixed, permeabilized with Cytofix/Cytoperm (BD PharMingen), and then stained with a PE-anti-IFN-g mAb (BD PharMingen). The expression of intracellular IFN-g by CD8 þ T cells was analyzed with a flow cytometer. Supernatants from day 6 and day 12 cultures were collected and analyzed for cytokine secretion with a human Th1/Th2 CBA kit (BD PharMingen).
Allogeneic MLR
Evaluation of T-cell responses
Immature DCs were generated from PBMCs of normal donors with the HLA-A*0201 genotype and cultured with equal numbers of tumor cells for 16 hours. After washing, tumor cell material-pulsed DCs (1.5 Â 10 5 cells/well) were cultured with autologous CD8-enriched T cells (1.5 Â 10 6 cells/well) in RPMI medium supplemented with 10% human AB-type serum (BioWhittaker, Walkersville, MD) in a 24-well plate. Autologous CD8-enriched T cells (80% pure) were prepared by removing adherent cells and CD4 þ T cells with anti-CD4-coated magnetic beads and a Magnetic Particle Concentrator (Dynal Biotech, Oslo, Norway). IL-2 (20 U/ml) was added into the culture on day 1, 3, and 6. On day 10, the T cells were restimulated with irradiated autologous PBMCs pulsed with 50 mg/ml of an HLA-A*0201-restricted HER2 peptide (HER2, 369-377:KIFGSLAFL, Research Genetics, Huntsville, AL). 30 IL-2 (20 U/ml) was added into the culture on days 11 and 14. On day 17, T cells (1 Â 10 5 cells/well) were stimulated with irradiated (8000 rad) T2 cells (5 Â 10 4 cells/well) pulsed in advance for 3 hours with 50 mg/ml of the HER2 peptide or a control HLA-A*0201-restricted, HPV-16 E6 peptide (E6, 18-26:KLPQLCTEL, Research Genetics). 31 The secretion of IFN-g in the culture supernatant was determined after 48 hours using a human Th1/Th2 CBA kit (BD PharMingen). The number of viable cells at the beginning (day 0) and the end of each stimulation procedure (days 10 and 17) was determined by the trypan blue exclusion assay. The cytotoxicity was determined by a europium-ligand release assay (Wallac, Turku, Finland). The counts of culture with unlabeled T2 cells were subtracted from those of cultures with peptide-pulsed T2 cells before calculating the specific lysis.
Animal experiments
Murine DCs were generated by culturing bone marrow cells with RPMI-1640 medium supplemented with 10% FBS, 500 U/ml of murine GM-CSF, and IL-4 (Peprotech) for 7 days as described. 26 CT-26 or B16-F1 tumor cells (ATCC, Rockville, MD) were transfected with either a control vector or a vector carrying the murine CD40L gene. Transfected cells were selected and cloned similarly to methods described above. Day-7 DCs were cocultured with irradiated (20,000 rad) CD40L-tumor cells for 48 hours at a one-to-one ratio. Mice (n ¼ . This experiment was repeated once using the same conditions.
Results
DCs can efficiently internalize tumor materials from frozen/thawed or irradiated tumor cells transfected with CD40L
Human cells (because they are most relevant to future clinical applications) were investigated initially in an in vitro system. The cDNA for human CD40L was transfected into a human lung cancer cell line (Fig 1a) to generate tumor cells that can both provide tumor antigenic materials and DC stimulatory signals. Immature DCs were generated by culturing adherent PBMCs with GM-CSF and IL-4 for 7 days. They expressed a typical surface staining phenotype of immature DCs (HLA-
À , and CD86 þ ) and can be induced to express a mature DC phenotype (CD86 high and CD83 þ ) after incubation with 1000 U/ml TNF-a for 40 hours (Fig 1b  and data not shown) . To determine the capacity of immature DCs to internalize tumor materials after different treatments, tumor cells, with or without surface CD40L (CD40L-tumor or vector-tumor cells, respectively), were labeled with a green fluorescent dye (PKH67) and treated with one cycle of freezing/thawing or irradiation (12,000 rad). Irradiation at this dose initiated only a slowly progressing apoptosis in the tumor cells, as about 13 and 41% of cells were stained positive with FITC-annexin V after 16 and 40 hours, respectively ( Fig  1c) . These treated tumor cells were then cultured with equal numbers of immature DCs. After 16 hours, a significant amount of green fluorescent material was observed in CD11c þ DCs cultured with various forms of tumor cells (Fig 2) . These results indicate that immature DCs were capable of internalizing antigenic materials from tumor cells with or without CD40L expression on the surface. Similar results were observed after coculturing for 40 hours (data not shown). Flow cytometric analysis revealed that 65% (64/99) of all CD11c þ DCs contained green fluorescent tumor materials (Fig 3a, (Fig  3a, right panel) . These results indicate that immature DCs appeared to engulf tumor materials more efficiently when CD40L-tumor cells were treated with freezing/thawing. It is likely that coculture with irradiated CD40L-tumor cells led to maturation of immature DCs and thus downregulated their capacity to internalize tumor materials. There were only a few necrotic cells (o5%) in the culture up to 40 hours after irradiation (Fig 1c) . Therefore, under this condition, necrotic cells should not have a major role in the uptake of tumor materials by DCs and the induction of DC maturation.
Only irradiated CD40L-tumor cells can efficiently
The mixture of cells was collected and the distribution of internalized green tumor material in DCs expressing CD11c (all DCs) or CD83 (mature DCs) was evaluated. Around 20% of green fluorescent material was associated with CD11
þ DC after 4 hours of coculture with irradiated vector-tumor or CD40L-tumor cells, while 60-70% of green fluorescent tumor material was associated with CD11c þ DC after 16 and 40 hours (Fig 3c) . The proportion of green fluorescent tumor material associated with CD83
þ DCs after culturing with irradiated CD40L-tumor cells for 4, 16, or 40 hours was similar to that associated with CD11c þ DCs (Fig 3c and  d, open bars) . However, less than 20% of green fluorescent tumor material from irradiated vector-tumor cells was associated with CD83 þ DC even after 40 hours (Fig 3d, closed bars) . These results demonstrate that after coculturing immature DCs with irradiated CD40L-tumor cells, a significant amount of tumor material was internalized by CD11c þ DCs, and that most of these DCs also became CD83 þ within 16 hours. Coculturing immature DCs with irradiated vector-tumor cells also resulted in efficient internalization of tumor materials into CD11c þ DCs, but the majority of them remained CD83 À even after 40 hours.
Only irradiated CD40L-tumor cells induce a significant secretion of pro-Th1 and pro-inflammatory cytokines by DCs
DCs are known to dictate and modulate immune responses by releasing various cytokines and chemokines. A significant level of IL-12p70, in addition to substantial amounts of IFN-g and several proinflammatory cytokines including IL-6 and TNF-a, was detected only in the culture containing DCs and irradiated CD40L-tumor cells after 40 hours (Fig 4) . Significant levels of IL-8 were present under all four culture conditions, and the highest level was detected in the culture with irradiated CD40L-tumor cells. A low level of IL-10 and IL-1b was detected in the culture containing DCs stimulated with irradiated CD40L-tumor cells. These results indicate that coculturing immature DCs with irradiated CD40L-tumor cells drives the activation of DCs and the production of several pro-Th1 and proinflammatory cytokines. This cytokine and chemokine profile should foster the generation of an effective antitumor CTL response.
DCs cultured with irradiated CD40L-tumor cells induce a much stronger primary allogeneic MLR
We then evaluated the T-cell stimulatory function of these DCs. DCs cultured with irradiated CD40L-tumor cells clearly stimulated a much stronger allogeneic MLR than those cultured with frozen/thawed CD40L-tumor cells or vector-tumor cells (Fig 5a and c) . This result further demonstrated that irradiated CD40L-tumor cells were the most effective stimulus of DC maturation in our experimental setting. Nevertheless, DCs cultured for 16 or 40 hours with frozen/thawed or irradiated tumor cells, with or without CD40L expression, stimulated allogeneic MLR equally well in the presence of LPS (Fig 5b and d) . These results suggest that frozen/thawed or irradiated vector-tumor cells and frozen/thawed CD40L-tumor cells failed to provide necessary maturation stimuli for immature DCs, but they did not interfere with the ability of immature DCs to undergo maturation in the presence of a valid DC maturation signal such as LPS.
DCs cultured with irradiated CD40L-tumor cells preferentially promote the growth of CD8 þ T cells
To further investigate the influence of tumor materialpulsed DCs on the growth of T cells, DCs were cultured with tumor cells after different treatments as described above. After 40 hours, DCs were collected, washed and cultured with allogeneic T cells. T cells were harvested and examined on day 12, whereas the culture supernatant was Antigen loading and concurrent activation of DC K-J Liu et al collected on day 6 and day 12 for cytokine analysis. The highest number of T cells was recovered from the culture stimulated by DCs pulsed with irradiated CD40L-tumor cells, and more than 40% (37/92) of all CD3 þ T cells in the culture were CD8 þ (Fig 6a) . The majority (478%, 29/37) of these CD8 þ T cells expressed IFN-g after stimulation with PMA and ionomycin, indicating that they are in a rather activated state. The percentage of CD8 þ T cells of all CD3 þ T cells in the other three groups was lower than 13% (8/96, 5/94, and 12/96). These results strongly suggest that DCs cultured with irradiated CD40L-tumor cells can efficiently promote the growth of CD8 þ , IFN-g producing T cells. Similar results were also observed in the experiments using CD45RO-depleted autologous or allogeneic T cells (data not shown). Some cells expressed lower levels of CD3 and CD8. These cells were probably the CD56 þ cells and thus were not gated for analysis. Examination of the cytokine environment during T-cell stimulation indicated that the culture supernatant of T cells plus DCs pulsed with irradiated CD40L-tumor cells contained the highest level of IFN-g and TNF-a, and the lowest level of IL-5 (Fig 6b) . This cytokine profile should promote the development of Th1 and CTL responses. In contrast, the cytokine environment of the other three groups is more likely to favor a Th2 response (Fig 6b) .
DCs cultured with irradiated CD40L-tumor cells generate more Ag-specific T cells in vitro
It has been reported that the proto-oncogene HER2 was overexpressed in many cancers including the non-smallcell lung cancer. 32 The parental and transfected human lung cancer cell lines used in this study also expressed similar levels of HER2 on the surface (data not shown). To study the cross-presentation and T-cell stimulation function of tumor material-pulsed DCs, we have examined the ability of DCs to process tumor materials and For intracellular cytokine staining, proliferating T cells were collected and stimulated with PMA and ionomycin in the presence of GolgiStop for 6 hours. Cells were stained with an FITC-anti-CD8 mAb. After washing, cells were fixed, permeabilized, and then stained with a PEanti-IFN-g mAb. Expression of intracellular IFN-g by CD8 þ T cell was analyzed with a flow cytometer (a). Supernatants from day 6 and day 12 cultures were collected and analyzed for cytokine secretion (b).
generate HER2-specific T cells in vitro. DCs were obtained from normal donors with the HLA-A*0201 genotype and cultured with tumor cells after different treatments for 16 hours. These DCs were washed, irradiated, and then cultured with autologous (HLA-A*0201) CD8-enriched T cells in the presence of human AB-type serum. After 10 days, T cells were restimulated with irradiated autologous PBMCs pulsed with an HLA-A*0201-restricted HER2/369-377 peptide to enrich for HER2-specific T cells. Surviving T cells on day 17 were collected and stimulated with T2 cells pulsed with the HER2/369-377 peptide or a control HPV E6 peptide. We have found that only T cells initially stimulated with DCs cultured with either irradiated vector-tumor or CD40L-tumor cells were able to secrete a significant amount of IFN-g in response to T2 cells pulsed with the HER2/369-377 peptide (Fig 7a) . These results indicate that DCs cultured with irradiated tumor cells can process internalized tumor materials and present the HER2/369-377 epitope to autologous T cells. T cells initially stimulated with DCs pulsed with frozen/thawed tumor cells secreted little IFN-g. Therefore, it is not likely that the second stimulation with peptide-pulsed autologous PBMCs was priming, instead of boosting, the HER2-specific response.
The cell numbers from all four groups decreased in the first 10 days of stimulation probably due to the death of nonspecific autologous T cells. However, after two in vitro stimulations, a much higher number (44-fold) of T cells, initially primed by DCs pulsed with irradiated CD40L-tumor cells, were recovered (Fig 7b) . In addition, after four in vitro stimulations, significant cytotoxicity of these CD8 þ T cells against T2 cells pulsed with the HER2/369-377 peptide could be detected (Fig 7c) . In contrast, the number of T cells from the other three groups declined rapidly during the first two in vitro stimulations and these T cells died out during the subsequent stimulations. These results are consistent with our previous observations and indicate that DCs pulsed with irradiated CD40L-tumor cells are superior in supporting the growth of specific CD8 þ T cells during in vitro culture. (Fig 8a,b,e,f) . For the more immunogenic CT-26 tumor, vaccination of either irradiated CD40L-tumor or DCs pulsed with irradiated CD40L-tumor both provided protection in the majority of the mice (Fig 8g and h) . However, for the weakly immunogenic B16-F1 tumor, immunization with DCs pulsed with irradiated CD40L-B16-F1 tumor cells (Fig 8d) was better than vaccination with irradiated CD40L-B16-F1 tumor cells alone (Fig 8c) in inhibiting or delaying the growth of tumor. Vaccination with DCs pulsed with irradiated vector-tumor cells failed to provide such additional protection in both tumor models (data not shown). These results suggested that for certain weakly immunogenic tumors, the response to tumor vaccine consisting of DCs pulsed with irradiated CD40L-tumor cells might be more protective than that to tumor vaccine consisting of just the irradiated CD40L-tumor cells alone.
Animals vaccinated with
Discussion
DC-based clinical trials for advanced cancers with partial effectiveness have been reported. 6, 17, 33, 34 One aspect to improve current DC-based vaccines could be the source and format of tumor Ag. Both necrotic and apoptotic tumor cells have been explored as the source of Ag. However, the consequences of Ag presentation by DCs after internalization of materials from necrotic or apoptotic cells may be different. It has been proposed that immature DCs that have taken up Ag from apoptotic cells during normal tissue turnover may induce anergy in T cells or generate regulatory T cells as a mechanism of peripheral tolerance. 35 Nevertheless, some studies demonstrated that DCs can acquire Ag from apoptotic cells and induce Ag-specific T-cell responses. 12, 14, 15 Both apoptotic cells and lysate or supernatant of necrotic cells have been shown to induce DC maturation in some reports. 36, 37 DCs exposed to apoptotic cells mediated by virus infection or in the presence of inflammatory stimuli may undergo maturation. 38, 39 Rovere et al have demonstrated that a higher number of apoptotic cells may trigger DC maturation and increase their ability to crossactivate T cells. 13, 40 It has been shown that the maturation of DCs is better stimulated by necrotic tumor cells than by apoptotic tumor cells or primary tissue cells, probably due to the secretion of proinflammatory mediators or heat-shock proteins during necrosis. 36, 41 However, in other reports, immature DCs were not matured after coculturing with tumor cell lysate or supernatant of necrotic cells alone. [42] [43] [44] To reconcile these contradictory results, Salio et al 43 and Somersan et al 37 have suggested that DCs are triggered to maturation not simply by the death of surrounding cells, but also by other coexisting stimulatory signals. These factors include inflammatory cytokines, 42 heat-shock proteins released by dead cells, 37 and microbial materials (e.g., mycoplasma) contained in the cell lysate. 43 Feng et al 45 also demonstrated that only stressed apoptotic cells (but not nonstressed apoptotic cells) could efficiently stimulate DC maturation, possibly through upregulation of surface heat-shock proteins. Our results support the notion that exposure of immature DCs to necrotic or apoptotic cells may not be sufficient to induce DC activation. Additional stimulations are required to fully mature DCs. Since our tumor cell culture was free from mycoplasma contamination, it is likely that little (if any) heat-shock protein was released from the tumor cells under the conditions of our experiment, and hence DCs were not induced to maturation after coculturing with necrotic or unmodified apoptotic tumor cells. In our case, the concurrent signaling by functional membrane-CD40L is required and sufficient for optimal stimulation of DCs to secrete IL-12 and other proinflammatory cytokines, and to promote the growth of CD8 þ T cells. This is further supported by a recent study indicating that both crosstolerance and crosspriming require the presence of mature DCs and the determining factor is whether DCs receive an additional activation signal from CD4 þ T cells, most likely through CD40-CD40L interaction. 46 A combination of DC-based cancer vaccines with costimulatory molecules, cytokines, and chemokines could provide potential activation signals and allow for a greater control of DC functions particularly in the microenvironment of vaccine injection site. Soluble forms of these immune-regulatory mediators are convenient to handle, but may have limitations due to a short half-life if delivered locally, or undesired toxicities if administered systemically. One strategy of enhancing the efficacy of DC-based vaccine is to use gene-modified tumor cells as a provider of both tumor Ag and activation stimulus for DCs in vitro. In our study, coculturing immature DCs with frozen/thawed or irradiated vector-tumor cells resulted in uptake of tumor materials by DCs, but failed to induce DC maturation and activation. In contrast, irradiated, but not frozen/thawed, CD40L-tumor cells can efficiently induce the maturation and activation of DCs in the absence of additional cytokines. DCs cultured with irradiated CD40L-tumor cells secreted not only IL-12 but also a substantial amount of IL-6, IL-8, IFN-g, and TNFa. Thus, vaccination with such tumor material-loaded, activated DCs might create an inflammatory microenvironment at the injection site, and effectively promote the generation of Th1 and CTL responses. Indeed, more IFNg-producing, CD8 þ T cells were obtained after stimulating allogeneic or autologous T cells with DCs precultured with irradiated CD40L-tumors. Although soluble CD40L may provide a similar stimulus, results reported previously 47 and from our own experiments (data not shown) indicate that its stimulatory effect might be lower than that of membrane-bound CD40L. We have also observed that DCs cultured with either irradiated vector-or CD40L-tumor cells can both process internalized tumor materials and generate HER2/369-377-specific T cells in vitro. However, T cells survived for a longer period in vitro if they are initially primed by DCs cultured with irradiated CD40L-tumor cells. Since DCs stimulated with irradiated vector-tumor cells secrete very little IL-12, it is possible that a large amount of IL-12 may be more important in the maintenance (in contrast to the priming) of peptide-specific CD8 þ T cells. Nevertheless, other CD40L-mediated signals may also increase the ability of DCs to support the growth of CD8 þ T cells. DCs cocultured with irradiated vector-tumor cells did not mature efficiently, but could still induce HER2/369-377-specific T cells (Fig 7a) . One possible explanation is that these immature DCs also secreted a substantial amount of IL-6 (Fig 4) . Several investigators have reported that IL-6 plays an important role in the induction of CTL in vitro.
48-51 A combination of IL-6 and IL-12 is likely to further enhance the survival of CTLs, 51 as occurs in cultures containing DCs pulsed with irradiated CD40L-tumor cells. Our results are in agreement with these previous findings.
We have observed that a low but significant amount of IL-10 was present in the culture containing DCs and irradiated CD40L-tumor cells. IL-10 has been shown to suppress immature DC development. [52] [53] [54] However, the presence of IL-10 in our cultures did not seem to interfere with the induction of CD83 expression on DCs, and the ability of DCs to mediate a strong allogeneic MLR. It has been shown that mature DCs are more resistant to the inhibitory effect of IL-10. 52, 55 Therefore, it is likely that DCs cocultured with irradiated CD40L-tumor cells have undergone maturation and activation before the IL-10 can act. Signaling through CD40L and the presence of TNF-a may counteract the inhibitory effect of IL-10 as well. 56 Alternatively, IL-10 in this setting may be stimulatory, since IL-10 was shown to promote the maintenance of tumor-specific CD8 þ T-cell effector function. 57 This is in agreement with our finding that CD8 þ T cells initially stimulated with DCs cultured with irradiated CD40L-tumor cells survived longer during the in vitro stimulation procedure. The failure of frozen/ thawed CD40L-tumor cells to induce DC maturation may be due to the denaturation of surface CD40L during the freezing/thawing treatment. Although most tumor cells remain intact after only one cycle of freezing/thawing, it is also possible that frozen/thawed CD40L-tumor cells are internalized or break down early in the culture before sustained contact with DCs needed for efficient induction of maturation is achieved.
This study was initiated mainly to evaluate the potential use of DCs pulsed with CD40L-tumor cells as a cancer vaccine in future clinical studies. Therefore, human tumor cells and monocyte-derived DCs were used in our in vitro system. We have demonstrated that pulsing DCs ex vivo with irradiated CD40L-tumor cells can result in simultaneous internalization of tumor materials and activation of DCs without adding exogenous cytokines. Pulsing with irradiated CD40L-tumor cells proved to be a better strategy for increasing the capacity of DCs to stimulate CD8 þ T cells than pulsing with unmodified tumor cells. Also, the in vitro irradiated CD40L-tumor cell-stimulated production of various pro-Th1 cytokines and proinflammatory chemokines should increase the efficacy of vaccination in vivo. It is likely that the secretion of IL-6, IL-8, IFN-g, and TNF-a at the vaccination site by these activated DCs might attract and/or activate cells of the innate immune system such as NK cells and eosinophils and lead to an amplification of the immune responses. Thus, pulsing DCs with irradiated CD40L-tumor cells in vitro may allow Ag loading and activation of DCs to be better controlled, and vaccination with DCs pulsed with irradiated CD40L-tumor cells may have a greater therapeutic effect than vaccination with irradiated CD40L-tumor cells alone. Our preliminary experiments demonstrated that animals immunized with DCs pulsed with irradiated CD40L-tumor cells were indeed better protected against a weakly immunogenic tumor cell line. It is possible that tumor cell-based vaccines and DC-based vaccines may generate different immune responses or involve different effector cells. We are currently conducting animal experiments to clarify the underlying mechanisms of these two different immunization strategies. Since most human cancer cells are likely to be of low immunogenicity, our results suggest that DCs pulsed with irradiated CD40L-tumor cells could be useful clinically and may provide the basis of cancer vaccines that could be tested in future clinical studies. Since sufficient tumor cells may not always be available and freshly isolated tumor cells are difficult to transfect, such an approach (using autologous gene-modified tumor cells) may be inappropriate for the treatment of some cancer patients. However, in several recent clinical studies of cancer vaccine, unmodified or gene-modified allogeneic tumor cells were chosen as the source of tumor Ag. 18, 58 The basis for this choice was the assumption and observation that tumor cells from different patients express some of the same TAA (e.g., CEA, MUC-1, and HER2/neu), and that DCs are superior in crosspresentation. 59, 60 Therefore, it is possible that well-characterized, allogeneic tumor cell lines transfected with CD40 ligand could be used as the source of tumor Ag to pulse and stimulate DCs in a future clinical application of our proposed vaccination strategy.
